Development of a Conceptual Model of Disease Progression for Use in Economic Modeling of Chronic Obstructive Pulmonary Disease. by Tabberer, M et al.
1 
 
Development of a Conceptual Model of Disease Progression for Use in 
Economic Modeling of Chronic Obstructive Pulmonary Disease 
Maggie Tabberer, MSc,*, Sebastian Gonzalez-McQuire, MSc, Hana Muellerova, PhD, Andrew Briggs, 
DPhil, Maureen Rutten-van Molken, PhD, Mike Chambers, MSc, David A. Lomas, PhD FRCP 
Value Evidence and Outcomes, GSK R&D, Stockley Park, UK (MT); Formerly Global Health Outcomes, GSK 
R&D, Stockley Park, UK (SGM); Worldwide Epidemiology, GSK R&D, Stockley Park, UK (HM); Institute of 
Health and Wellbeing, University of Glasgow, Glasgow, UK (AB); ICON Health Economics, Morristown, NJ, USA 
(AB); Institute for Medical Technology Assessment, Erasmus University/Erasmus Medical Centre, Rotterdam, The 
Netherlands (MRvM); Global Market Access and Healthcare Solutions, GSK, Brentford, UK (MC); Wolfson 
Institute for Biomedical Research, University College London, London, UK (DAL). 
*Address correspondence to: 
Maggie Tabberer 
Director, Respiratory Patient Focused Outcomes, Value Evidence and Outcomes, GSK 
Stockley Park West (B10), Uxbridge, Middlesex UB11 1BU, United Kingdom 
Tel: +44 208 990 2041; Fax: +44 208 990 3505 
Email: margaret.x.tabberer@gsk.com 
 
Funding: This study was funded by GSK. 
 
This work has previously been published in abstract form and was presented in two parts at the International Society 
for Pharmacoeconomics and Outcomes Research - 14th Annual European Congress 2011 (literature review) and at 
the International Society for Pharmacoeconomics and Outcomes Research - 15th Annual  European Congress 2012 




Key words: Conceptual model, chronic obstructive pulmonary disease (COPD), literature review, Delphi Panel, 
economic modeling  
 
Running Title: COPD conceptual model for economic modeling 
 
Abbreviated Title: Development of a conceptual model of COPD for economic modelling 
 
Word count: 3934 
 
 
Financial support for this study was provided entirely by GSK. The funding agreement ensured the authors’ 
independence in designing the study, interpreting the data, writing, and publishing the report. The following authors 






Background. To develop and validate a new conceptual model (CM) of chronic obstructive pulmonary disease 
(COPD), for use in disease progression and economic modeling. The CM identifies and describes qualitative 
associations between disease attributes, progression and outcomes. 
Methods. A literature review was performed to identify any prior published CM or literature reporting on the 
patient impact and association of COPD disease attributes with outcomes. After critical analysis of the literature, a 
Steering Group of experts from the disciplines of health economics, epidemiology and clinical medicine was 
convened to develop a draft CM, which was refined using a Delphi process. The refined CM was validated by testing 
for associations between attributes using data from the Evaluation of COPD Longitudinally to Identify Predictive 
Surrogate Endpoints (ECLIPSE). 
Results. Disease progression attributes included in the final CM were history and occurrence of exacerbations, lung 
function, exercise capacity, signs and symptoms (cough, sputum, dyspnea), cardiovascular disease comorbidities, 
‘other’ comorbidities (including depression), body composition (body mass index), fibrinogen as a biomarker, 
smoking, and demographic characteristics (age, gender). Mortality and health related quality of life were 
determined to be the most relevant final outcome measures for this model, intended to be the foundation of an 
economic model of COPD. 
Conclusion. The CM is being used as the foundation for developing a new COPD disease progression model. The 
CM provides a framework for analysis of patient level data and is available as a reference for the implementation of 





Disease progression and economic modeling of healthcare interventions, particularly pharmaceutical 
technologies, has traditionally focused on the estimation of costs and benefits, employing measures of efficacy 
collected during clinical trials or observational studies. In chronic obstructive pulmonary disease (COPD), disease 
progression and economic models have mainly focused on lung function and exacerbations as the main attributes of 
the disease. Although these are relevant measures of disease severity and progression, research has demonstrated 
that COPD is a systemic disease with multiple attributes that impact on disease progression and health outcomes [1]. 
The development of new therapeutic interventions for COPD is increasingly focused on these systemic effects, 
which may be associated with simultaneous changes in several intermediate outcomes, with potential for differential 
efficacy in different COPD phenotypes. Consequently, any new disease progression or economic model developed 
for COPD to support such interventions should take into consideration multiple aspects of the disease, both 
symptoms and health related quality of life experienced by the patient and those that affect clinical progression. 
A recent update of guidelines for good economic modeling research practice recommended the development 
of a conceptual model (CM) as a basis for model development [2]. A CM representing a particular disease should 
ideally illustrate the relationship between determinant aspects of the disease and its outcomes that can be identified 
and measured, thereby providing a framework that highlights potential interactions between attributes and helps the 
researcher to avoid any ‘double counting’ of effects in the subsequent economic model. A CM also helps to illustrate 
how a healthcare intervention which may be directed at changing one aspect of the disease may have an indirect 
impact on other aspects of the disease that have not been measured in clinical trials. 
The objective of the present study was to develop a CM for use in modeling disease progression and 
subsequently to underpin an economic model (to be reported separately) for the assessment of cost effectiveness of 
therapies in COPD. The CM identifies and describes relationships between disease attributes, disease progression 
and health outcomes. These relationships were then tested using existing data from observational and clinical 
cohorts to ensure only relevant measurable attributes were included in the final CM (the CM was limited to those 





Literature review. We conducted a systematic literature search to identify publications of CMs in COPD, 
including those represented in economic models, to identify studies reporting the associations between disease 
attributes and their prognostic value in terms of both disease progression and health outcomes. The term ‘attribute’ 
is used here to collectively refer to any determinant, endpoint or health outcome associated with the measurement of 
COPD. The attributes of interest for the purposes of this study are those that may affect health status (health-related 
quality of life) and mortality, either directly or by influencing an intermediate outcome such as the frequency of 
exacerbations.  
The literature search was conducted using MEDLINE and EMBASE, and was limited to articles published in 
the English language from 2000 to 2012. Publications earlier than 2000 were excluded to reflect more recent 
advances in disease understanding. The search strategy was designed to identify studies reporting CMs and 
relationships, associations (correlations and/or regression analyses) with COPD endpoints and disease progression. 
The terms used in the literature search included: conceptual model, regression model, associations, COPD, endpoint 
model, correlation, conceptual framework, relationships, attributes, endpoints and outcomes. The review included 
studies presenting results of associations between COPD disease attributes and health outcomes. Attributes were 
identified that either directly affect the course of the disease or that modify other ‘intermediate’ attributes that have 
prognostic value. Clinical trials specifically designed to report the efficacy and/or effectiveness of therapeutic 
interventions (pharmacologic treatments, pulmonary rehabilitation etc.), were excluded from the results of in this 
search. Such trials are not designed primarily to report on the relationships between disease attributes and health 
outcomes, and where this occurs the selection of attributes and outcomes is related to the effects of the intervention 
studied. Study design features (including duration of intervention, length of follow up and, particularly, inclusion 
and exclusion criteria) also mean that any associations reported may not be applicable to the broader disease concept 
of COPD over the course of the disease. Specifically, the aim of the review was to support development of a CM as 
an underlying structure for an economic model of COPD in which the effects of different interventions would be 
incorporated by applying (different) treatment effects to the baseline or ‘untreated’ disease progression model. 
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Whilst CMs relating to specific interventions have been developed (e.g. those aimed at the treatment of dyspnea), 
these include limited attributes and components related to the specific intervention.  
Steering Group and Delphi Panel Two groups were convened to guide the development of the CM. The first 
was a project Steering Group consisting of experts in health economics, epidemiology, and clinical medicine. 
Members of the Steering Group, all of whom are experienced COPD researchers and economic modellers, 
developed a draft CM of COPD (based on the literature review and informed by their own expertise) for testing by 
the second group, convened as a Delphi Panel. The role of the Delphi Panel was to refine the initial CM drawn up by 
the Steering Group. The Steering Group provided oversight of model development, including quantification and 
validation of associations between attributes, and consequently guided development of the disease progression and 
economic model. The members of both the Steering Group and the Delphi Panel were reimbursed for time spent 
completing the questionnaires and participating in the panel.  
Delphi methodology is a recognized method for gaining expert consensus and has been used extensively 
across the social sciences [3–5]. It is useful for gaining the input of a variety of experts in a timely and efficient 
manner through a series of questionnaires and feedback; two or three rounds of questionnaires are usually required 
to gain consensus. The method encourages equal participation of all panelists and removes some negative aspects of 
group dynamics from the process. Five to eight panelists are suggested as optimal. In this study, five academics with 
a wide range of clinical and epidemiological experience in COPD were invited to participate. Panel members were 
selected to ensure that all relevant aspects of COPD from the literature review and from personal expertise were 
identified in the final CM. 
A Delphi Panel exercise using modified methodology was conducted by email between 23 January 2012 and 
15 February 2012. Two rounds of questionnaires were conducted to gain consensus. In round one, panel members 
were sent the draft CM and an initial questionnaire with instructions for individual completion. The information 
returned by panel members was then tabulated and collated. A second questionnaire (round two), following the same 
general format of the first, was circulated to panel members together with the anonymized, collated results of round 
one, and the individual panel member’s previous responses to each question. Personalized supplementary questions 
were also included where needed, to seek clarity on responses from round one. 
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The questionnaires consisted of a number of questions related to the draft CM and included graphical 
breakdown of sections of the CM for simplification and to allow for systematic analysis of the different attributes of 
COPD. Panel members were asked to perform the following tasks: (1) assess the disease attributes and concepts 
included in the draft CM for completeness; (2) suggest additional attributes that might be missing; (3) evaluate the 
relationships between attributes and the direction of those relationships; (4) qualitatively estimate the strength of the 
relationships (high/medium/low) to indicate which attributes were likely to be essential for quantifying disease 
progression and health outcomes; (5) suggest additional relationships and/or directional links that might be missing; 
and (6) recommend the most appropriate measure for each attribute. 
The graphical breakdown of the draft CM comprised sections on body composition, comorbidities, 
exacerbations, lung function, exercise capacity, signs and symptoms, triggers, depression, fibrinogen, and 
demographic and other characteristics. For each section, panelists were also asked to comment on the proposed 
measurement metrics for the attribute and suggest other preferred measures. 
Associations between attributes. Disease attributes in the CM were divided into two categories: baseline 
attributes (those that do not change over time, change independently of disease progression, or for which the impact 
on disease progression is constant over time), and disease progression attributes (those for which impact on disease 
progression changes over time).  
To test the two levels of association, we first implemented a pairwise analysis using baseline variables to 
explore strength and direction of effect among all disease progression attributes identified in the CM (lung function, 
exacerbations, signs and symptoms, and exercise capacity). We then evaluated the pairwise associations to evaluate 
inter-dependent associations over time, and applied random coefficient models to evaluate endogeneity and the 
potential for non-linearity, with an appropriate distribution to establish the strength of the association over time. For 
both analyses we used data from the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints 
(ECLIPSE) study [6,7]. The ECLIPSE population comprised 2164 clinically stable COPD patients, 337 smokers 
with normal lung function and 245 never smokers; only data from the COPD patients was considered during the 
development of the CM. At baseline, COPD patients were older, had more smoking pack years, were more 
symptomatic (as reported by the modified Medical Research Council Questionnaire [mMRC] and the COPD-
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specific version of the St. George’s Respiratory Questionnaire [SGRQ-C]), had more comorbidities, and showed 
airflow limitation compared with smokers with normal lung function and never smokers.  
Significance testing of associations between attributes and of attributes with final health outcomes both at 
baseline (to establish association between attributes) and longitudinally (to establish associations with changes over 
time in attributes) supported their categorization, and confirmed which attributes could be fully quantified in the 
subsequent disease progression model. The CM was thereby designed to guide the development of a disease 
progression model. 
The estimated associations and direction of effect were assessed by the Steering Group for clinical 
plausibility. To assess the strength of effect, both at baseline and over time, the exacerbation risk equations used the 
Wald chi-square test; other risk equations used the t-test. If the P-value was ≥0.05, the association was deemed non-
statistically significant. Associations between attributes postulated in the draft CM were excluded from the final CM 
if no significant association was seen when the relationships were tested against the ECLIPSE data. 
Attributes categorized as baseline within the model were: body composition (body mass index, BMI), 
cardiovascular disease (CVD) comorbidity, depression, fibrinogen, smoking, exacerbation history and demographic 
characteristics. Disease progression attributes were: exacerbations, symptoms, exercise capacity and lung function . 
Final health outcomes defining the health status of the patient were mortality and health related quality of life.  
Final conceptual model. The CM was then refined based on the results of the Delphi consultation, available 
data and confirmation of associations at baseline and longitudinally. The Steering Group assessed whether there 
were sufficient data available to quantify the effects of associations prior to finalizing the CM; this pragmatic 
approach was taken to ensure that the final CM was fit for its intended purpose as a basis for economic modeling.  
Role of the funding source. The literature review was performed by SGM, who was an employee of GSK at 
the time. The Steering Group and Delphi Panel members were chosen and convened by MT, HM, MC (all current 
employees of GSK) and SGM, and members entered into a contract with GSK. The Delphi Panel questionnaire was 






Literature review. The MEDLINE and EMBASE database searches yielded a total of 443 citations. After 
review of abstracts, 274 of the 443 citations were rejected. Of the 169 full-text articles retrieved for potential 
inclusion, 125 were excluded during the second-level selection process. Thus, a total of 44 published papers were 
identified that reported CMs and/or associations between attributes and health outcomes in COPD. Figure 1 depicts 
the article flowchart through the study selection process, and reasons for article exclusion.  
Attributes and health outcomes were categorized as dependent or explanatory according to the distinction 
made in the source literature between ‘cause’ (explanatory; e.g. exacerbations) and ‘effect’ (dependent; e.g. worse 
lung function). The frequency with which each was reported was then used to identify associations and their 
directionality (Figure 2). The count reflects the number of times a particular disease attribute was reported in the 
literature as being associated with either another attribute or a health outcome of COPD. A total of seven studies 
reporting CMs of COPD, which also reported associations between attributes, and 37 studies reporting at least one 
association between endpoints and disease progression were found in the literature. Of the seven CMs examined, six 
described a single aspect of COPD: cognitive function [25], dyspnea [24], brain function [8], design of patient 
related interventions [17], activity [14] and functional performance [26]. Only one study [22] described a broader set 
of determinants of health status in COPD patients: physiological functioning, patient complaints, functional 
impairment and health related quality of life. 
Of the 44 published papers, 31 used regression analysis to estimate associations between attributes of COPD, 
including symptoms (mainly dyspnea), health status, exercise, lung function, exacerbations, quality of life, 
biomarkers, comorbidities, mortality and healthcare utilization. The attributes identified are shown in Figure 3. 
Exercise capacity was reported to be associated with a variety of attributes of COPD (symptoms, health status, lung 
function and exacerbations), as well as with health outcomes (hospitalizations), highlighting the need to consider 
this attribute when conceptualizing COPD. Although some were identified in the review, interventional studies of 
pharmacologic treatment and pulmonary rehabilitation were excluded from the development of the CM which 
represents the natural history of the disease process, only observational studies were included. Interventional studies 
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are usually selective in the population enrolled and typically have a limited duration of both intervention and follow 
up.   
The literature review did not identify any CM that described the relationships between all aspects of the 
disease within one framework. The need to develop a CM of COPD that reflects current and emerging disease 
understanding, and which can support the development of a disease progression model was confirmed. 
Steering Group-based draft conceptual model. The draft CM developed by the Steering Group included 
attributes of COPD, baseline characteristics and other factors that might influence disease progression, such as 
psychological and emotional factors. To simplify this draft model attributes were grouped, e.g., physical signs and 
symptoms of COPD were aggregated together. Hypothesized directions of associations were also included. The draft 
CM reflected the data available from the ECLIPSE dataset, and is shown in Figure 4a). Covariate data, available at 
baseline only, are shown at the top of the figure. 
Delphi Panel. Although the panel did not identify any new attributes for inclusion, they did identify that the 
CM should split the concept of signs and symptoms of COPD shown in the draft CM and display the individual 
signs and symptoms separately. Dyspnea, cough and/or sputum, fatigue and signs of hyperinflation, inflammation, 
and hypoxia were recommended as meaningful and measurable. The panel also recommended further changes to 
split exacerbations into different levels of severity, and to specify CVD separately from ‘other’ comorbidities. 
The panel proposed some additional links and recognized that the relationships between individual attributes 
differ in strength, with some relationships having a greater impact on disease progression health status and mortality 
than others (Table 1). The panel also identified that the strength of a relationship between two attributes may differ 
when used to describe (baseline) stratification of patients than when used to describe disease progression. Panelists 
also indicated where relationships existed but were considered too weak to independently drive disease progression 
and health outcomes. 
Associations between attributes. The relationships proposed in the draft CM and modified by the Delphi 
Panel were tested using data from the ECLIPSE cohort.  
Correlation analyses of all baseline variables confirmed the direction of effect and showed statistical 
significance, except for the associations between CVD comorbidities and exacerbations, and between depression and 
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exacerbations (Table 1). All of the proposed associations over time between the explanatory and dependent variables 
were shown to be significantly associated (P < 0.0001) over time (e-Appendix 1). 
Final conceptual model. The attributes included in the final CM were: exacerbations, lung function, exercise 
capacity, signs/symptoms (cough, sputum, dyspnea), CVD comorbidities, ‘other’ comorbidities (including 
depression), body composition (BMI), fibrinogen as a biomarker, smoking, exacerbation history and demographic 
characteristics (age, gender). Mortality and health related quality of life were agreed to be the most relevant (final) 
health outcome measures. Some relationships and attributes in the draft CM were found difficult to quantify due to 
lack of prior published evidence and/or data available in the ECLIPSE cohort and were therefore excluded from the 
refined CM. These included infections, environmental factors, psychological/emotional factors, socioeconomic 
status and ethnicity. 
In the final CM, exercise was identified as having an independent effect on both exacerbation frequency and 
lung function. Intuitively this makes sense as increased exercise (or physical activity) is likely to improve lung 
function [52]. Exercise might also be associated with a reduced exacerbation rate independently of any lung function 
effect [53,54]. However, rather than measuring the patient’s usual physical activity over time [55] the 6-minute walk 
test distance (6MWD) measures exercise capacity at a point in time [56]. Although 6MWD represents a widely used 
and standardized measure of exercise capacity, it can be influenced by patient motivation and the expected 
relationship between exercise and lung function may not be demonstrated in all patient cohorts where 6MWD is 
measured [57]. Therefore, the directional effect of 6MWD on lung function was removed in the final CM. In the 
final model, the (uni-directional) associations between forced expiratory volume in 1 second (FEV1), exacerbations 
and 6MWD were retained to demonstrate the influences of FEV1 and exacerbations on 6MWD. The final CM is 
presented in Figure 4b. 
The final CM was then tested to validate the relationships identified using data from the TORCH study, a clinical 
study including optimization of therapy with a 3-year follow up designed to reflect clinical practice. Long-term 
observation of health-related quality of life and, particularly, mortality (the final outcomes of the CM) were possible. 






Disease progression and economic models used to support economic evaluations of healthcare interventions 
should be based on CMs that describe the relationships between all relevant aspects of the disease and relevant 
health outcomes. Although there is considerable published evidence describing the associations between specific 
aspects of the disease, such as symptoms and health outcomes, the indirect relationships with disease progression are 
not addressed. No study has previously developed a CM that seeks to understand the relationship between all 
relevant attributes and health outcomes in the context of COPD disease progression.  
The CM was developed using a two-step approach that allowed for an assessment of evidence from existing 
CMs to be combined with clinical expertise and other specialties (the attributes identified in the literature and by the 
Delphi panel). The final CM, intended to underpin our economic model of COPD was then refined using existing 
baseline and longitudinal COPD patient level data (from the ECLIPSE and TORCH studies) to provide a framework 
for understanding the factors influencing COPD disease progression and health outcomes. This methodology 
approach to developing a CM should ensure that relevant aspects of a disease are considered. 
The literature review identified some studies reporting CMs of aspects of disease progression in COPD 
patients and provided a basis for the development of the draft CM by the Steering Group. It also identified the 
important attributes required to represent disease progression and health outcomes in COPD and highlighted the 
need to qualitatively characterize both COPD disease progression and health outcomes and to quantitatively test the 
resulting CM. Despite the breadth of the initial literature review that was conducted, relatively few (n = 44) 
publications were identified for data extraction. Of a total of 443 citations that were identified using the pre-selected 
range of search terms, 399 were deemed unsuitable primarily because they described clinical trials or health 
interventions in a proscribed sample of the overall COPD population rather than conceptual models reporting 
relationships between attributes, or because their primary focus was not on COPD. Interventional studies are also 
usually limited in duration of both intervention and follow up as well as in the attributes measured. The intervention 
studied will drive both the attributes included and the population studied; for example clinical trials of 
bronchodilator therapies typically recruit symptomatic patients with limited or no history of COPD exacerbations 
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who are not representative of the total COPD population. Although the relative lack of suitable publications 
somewhat hindered the development and validation of the CM described here and can therefore be considered a 
limitation, it may also reflect that there exist unmet needs in the economic modeling of COPD disease progression.  
The use of a modified Delphi approach refined the draft CM by adding more parameters into the model and 
estimating directions and strength of associations based on clinical experience. The panel endorsed most of the 
attributes proposed by the Steering Group in the draft CM and contributed significantly to the decisions made 
around inclusion and exclusion of parameters and direction of associations reflected in the final CM.  
The revised draft model, following input from the Delphi Panel, provided a detailed picture of all possible 
attributes and associations describing COPD disease progression. However, implementation of such a 
comprehensive CM as a disease progression model for economic evaluation requires large amounts of data, which 
may be challenging to obtain and analyze. The approach used to validate the associations between attributes and 
implement the revised draft of the CM was, by necessity, pragmatic, in that it was informed by the availability of 
evidence to support a quantitative estimation of the associations and correlations proposed by the Delphi Panel. The 
use of patient-level data from the ECLIPSE study was essential in permitting a quantification of the relationships 
within the CM. This dataset includes measures of the majority of the attributes identified, with the exception of 
some socio-economic and environmental factors. 
Quantification of the associations described in the CM may also be limited by the initial use of a single 
cohort of patients recruited in secondary care (ECLIPSE) to determine the relative strength and direction of 
relationships between attributes. The ECLIPSE cohort was used as the only large-scale study in which all of the 
attributes included in the analysis were measured, and in which the follow-up period was of sufficient duration for 
health outcome data to be recorded. Exploration of the associations between the selected attributes using pairwise 
correlation showed that most were statistically significant. Although statistical significance of these correlations 
could be expected based on the relatively large size of the ECLIPSE study we believe that the selected attributes do 
impact patients’ disease progression in COPD. The current study only assessed the existence of longitudinal 
associations between the disease progression attributes (lung function, exacerbation, symptoms and exercise 
capacity). A further limitation is that ECLIPSE did not include data that enabled an assessment of the impact of 
patient knowledge, attitude, and skills (such as illness perceptions, coping behavior, and self-management abilities) 
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to affect disease progression. Further research estimating relationships between baseline parameters and their 
longitudinal correlation with other attributes would improve understanding of how best to use these parameters in 
disease modeling.  
The strength of the present CM lies in the thorough and stepwise approach to its development, starting with a 
broad perspective of the disease, where all potential associations between attributes were considered, and only then 
focusing the CM to reflect the underlying purpose for its development as a basis for economic modeling of the 
disease. Validation of the draft CM using clinical experts, health economists and data from the ECLIPSE study 
resulted in a robust and comprehensive CM that can guide future disease modeling. For practical reasons, patients 
and caregivers were not included in our development of the CM: their involvement in further validation exercises is 
desirable.  
To date, conceptual modeling to support health economic evaluation has not been widely used in a formal 
sense. However, interest in the formal use of CMs to support health service decision making is growing. The 
recently reported joint Society for Medical Decision Making (SMDM)/ International Society for 
Pharmacoeconomics and Outcomes Research (ISPOR) Task Force on modeling devoted a whole paper to 
conceptualizing a model [2] and the National Institute for Health and Care Excellence (NICE) decision support unit 
recently produced a technical support document that included a discussion of conceptualizing economic models 
[59]. In developing the new CM of COPD presented in this paper, the principles of good modeling practice laid out 
in the SMDM/ISPOR Task Force 2 paper were followed as far as possible. The only part of this guidance that 
proved challenging to implement was II-3, which states that “although data are essential to a model, the conceptual 
structure should be driven by the decision problem or research question and not determined by data availability.” In 
the present study, when moving from draft to final CM, considerations about data availability from the ECLIPSE 
study were important. The CM should be refined as additional data become available. 
 In the NICE decision support unit report a distinction is made between ‘problem-orientated conceptual 
modeling’ and ‘design-orientated conceptual modeling’ [58]. Based on the present study, we suggest that the first 
step is ‘problem-orientated’ conceptual modeling, which involves deciding how the complexity of the ‘real world’ 
can be represented in a simplified modeling form. The CM may then be refined into a ‘design-orientated’ CM that 
takes into consideration how the model will be implemented in practice. During this step, it is legitimate to consider 
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data availability and how the parameters of the final model are to be estimated. While we agree with the principle 
listed in the SMDM/ISPOR Task Force Report, this sets a very high bar. In practice, the distinction between two 
forms of conceptual modeling made in the NICE decision support unit report was reflected in our experience of 
constructing a new model for COPD. We acknowledge that a draft model of potential associations for which there 
are no data would guide future exploration rather than limiting to a CM that is already modified for available data; 




We have developed and quantified a CM that reflects the heterogeneous nature of COPD, which includes a 
wide variety of COPD attributes impacting disease progression and health outcomes. The CM was refined using 
available evidence to validate the impact of the selected attributes on economic, humanistic and clinical outcomes. 
This CM is the foundation for the development of a new COPD disease progression model based on the ECLIPSE 
database. It has been formulated in a way that will facilitate its implementation in future disease progression and 
economic models, by serving as a framework for the analysis of patient-level data. The CM has applications both in 
clinical decision making as well as in economic modeling and provides an example for the development of CMs in 
other therapy areas for use in disease progression modeling. Future research should focus on the estimation of 
associations to incorporate the attributes in COPD that have been excluded from this CM, in order to understand the 
implications of their exclusion on the accuracy of the representation of disease progression and management, and 
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Table 1  Statistical Significance of Pairwise Correlations Between Explanatory (Baseline) Variables and Dependent (Disease Progression Attributes) Variables 
Based on ECLIPSE Data 






















BMI  <0.0001   <0.0001 <0.0001   
CRP <0.0001 0.002       
CVD/Comorbidities <0.0001   0.32 <0.0001 <0.0001 <0.0001 <0.0001 
Depression    0.0012     
Exacerbation  0.46 0.0012  <0.0001 <0.0001 <0.0001 <0.0001 
Exercise <0.001 <0.0001  <0.0001   <0.0001 <0.0001 
Fibrinogen <0.001 <0.0001  <0.0001     
Gender      0.90   
Lung function  <0.0001  <0.0001 <0.0001   <0.0001 
Mortality 0.0016 <0.0001 0.96 0.002 <0.0001  <0.0001 <0.0001 
HRQoL <0.0001 <0.0001 <0.0001 <0.0001 <0.0001  <0.0001 <0.0001 
Signs and Symptoms  <0.0001  <0.0001 <0.0001  <0.0001  
Smoking   0.054 0.16 <0.0001 0.008 <0.0001 0.0009 





Figure 1.  Results of literature search.  
COPD, chronic obstructive pulmonary disease. 
 
Figure 2.  Reporting of COPD attributes as dependent or explanatory variables from the literature review.  
Values give the number of reports of an association of a particular disease attribute with another attribute, or 
with a COPD health outcomes. Source studies are likely to have provided many associations (for different 
attributes).  
COPD, chronic obstructive pulmonary disease; HRQoL, heath-related quality of life. 
 
Figure 3.  List of (a) symptoms and (b) attributes associated with exercise, identified in the literature review.  
Values give the number of reports of the association with symptoms or other attributes.   
HRQoL, heath-related quality of life. *A subjective complaint is independent of a measurable symptom (i.e., 
patient complaint or feeling of impairment based on their own perception, without an actual measure of either). 
 
Figure 4.  (a) Draft conceptual model of COPD (proposed by the Steering Group) and (b) final conceptual 
model. 
COPD, chronic obstructive pulmonary disease; BMI, body mass index; CVD, cardiovascular disease; HRQoL, 
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Values give the number of reports of an association of a particular disease attribute with another attribute, or 
with a COPD health outcomes. Source studies are likely to have provided many associations (for different 
attributes).  
COPD, chronic obstructive pulmonary disease; HRQoL, heath-related quality of life. 
 
 
Total no. of reported associations = 730.  
Dependent variables: Symptoms: [8–24]; health status: [11,13–19,21,24,26]; exercise: [8–15,17,18,22–
25,27,28]; other: [10,12,17,25,29]; HRQoL: [10,11,13,17,18,22,23]; lung function: [8,11,12,15,17,18,21–
23,30,31]; mortality: [9,25,30,32–43]; exacerbations: [11,14,16,21,32,44–47]; hospitalizations: 
[25,27,32,33,40,47,48]; demographic: [12,15,22–24,30,49]; comorbidities: [8,49,50]; pulmonary rehabilitation: 










































































Explanatory variables: Symptoms: [11,13–15,17,19,22,24,25,27,28,31,34,35,37,40,43,45]; health status: 
[8,10,15,17,18,26–28,31,32,35,37,38,41,43,45,47]; exercise: [8,13,14,17,22,24,27,28,31,45,46]; lung function: 
[8,9,15–17,20,22,23,25,27,32,34,35,37,38,40,42,45,46,47]; other: [17,25]; HRQoL: [17,22,32,38,43,50]; 
demographic: [9,12,15,22,28,32,34,35,37,38,40,47]; comorbidities: [8,9,25,32,33,40,45,47,51]; exacerbations: 
[15,32,44–47,49]; biomarker: [9,21,30,39,48]; treatment: [8,29,36,43]; pulmonary rehabilitation: [19,25]. 
COPD, chronic obstructive pulmonary disease; HRQoL, heath-related quality of life. 
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Figure 3.  List of (a) symptoms and (b) attributes associated with exercise, identified in the literature review.  
Values give the number of reports of the association with symptoms or other attributes.   
HRQoL, heath-related quality of life. *A subjective complaint is independent of a measurable symptom (i.e., 




Total no. of reported symptoms = 196. Dyspnea: [14,15,17,22,24,31,34,38,40,43]; emotional: [27]; fatigue: 
[45]; mastery: [22]; anxiety: [11,13,19,27]; behavioral: [22]; subjective complaints: [22]; subjective impairment: 





Total no. of reported associations = 82. Symptoms: [8,13,14,17,22,24]; exercise: [8,22,24,27,28]; health status: 
[13,14,17,24]; HRQoL: [17,22]; lung function: [17,22,31]; other: [17]; demographic: [22,24]; exacerbations: 
[45,46]; hospitalizations: [27]. 
HRQoL, heath-related quality of life. *A subjective complaint is independent of a measurable symptom (i.e., 
patient complaint or feeling of impairment based on their own perception, without an actual measure of either). 
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6MWD, 6-minute walk test distance; BMI, body mass index; COPD, chronic obstructive pulmonary disease; 
CVD, cardiovascular disease; FEV1pp, forced expiratory volume in 1 second percent predicted; HRQoL, 
health-related quality of life; mMRC, modified Medical Research Council dyspnea scale; SGRQ, St-George’s 
Respiratory Questionnaire. Note: Final outcomes are influenced both by baseline covariates and attributes of 
COPD which change over time, as described in the central section of the model. 
